Anzeige
Mehr »
Donnerstag, 04.12.2025 - Börsentäglich über 12.000 News
Einmalige Investmentchancen in den potenziellen Gamechanger der Krebsbehandlung
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J68D | ISIN: CNE100001M79 | Ticker-Symbol: 08HH
Frankfurt
04.12.25 | 08:02
2,312 Euro
+1,05 % +0,024
Branche
Pharma
Aktienmarkt
ASIEN
1-Jahres-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD Chart 1 Jahr
5-Tage-Chart
SHANGHAI FOSUN PHARMACEUTICAL GROUP CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
2,2742,39214:40
2,2742,39014:39

Aktuelle News zur SHANGHAI FOSUN PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiFOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL OF DRUG CLINICAL TRIAL OF A SUBSIDIARY3
DiFOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION3
DiFOSUN PHARMA (02196): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTION5
DiFOSUN PHARMA (02196): POLL RESULTS OF THE RESOLUTION PROPOSED AT THE 2025 SECOND EXTRAORDINARY GENERAL MEETING HELD ON TUESDAY, 2 DECEMBER 2025 AND ELECTION ...5
FrFOSUN PHARMA (02196): CONTINUING CONNECTED TRANSACTIONS (1) ENTERING INTO THE CQ PHARMA MUTUAL SUPPLY FRAMEWORK AGREEMENT (2) ENTERING INTO THE FRAMEWORK ...5
18.11.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE ACCEPTANCE OF A SUBSIDIARY'S DRUG REGISTRATION APPLICATION1
07.11.FOSUN PHARMA (02196): NOTICE OF 2025 SECOND EXTRAORDINARY GENERAL MEETING23
SHANGHAI FOSUN PHARMACEUTICAL Aktie jetzt für 0€ handeln
07.11.FOSUN PHARMA (02196): NOTIFICATION LETTER AND REQUEST FORM TO NON-REGISTERED SHAREHOLDERS15
07.11.FOSUN PHARMA (02196): NOTIFICATION LETTER AND REPLY FORM TO REGISTERED SHAREHOLDERS1
07.11.FOSUN PHARMA (02196): FORM OF PROXY FOR HOLDERS OF H SHARES FOR THE 2025 SECOND EXTRAORDINARY GENERAL MEETING TO BE HELD ON TUESDAY, 2 DECEMBER 20251
07.11.FOSUN PHARMA (02196): ELECTION OF EXECUTIVE DIRECTOR AND NOTICE OF EGM3
04.11.FOSUN PHARMA (02196): H SHARE RSU FIRST GRANT UNDER THE 2025 H SHARE RSU SCHEME13
04.11.FOSUN PHARMA (02196): A SHARE OPTION FIRST GRANT UNDER THE 2025 A SHARE OPTION SCHEME1
29.10.Fangzhou Inc.: Fangzhou and Fosun Pharma Forge Strategic Alliance to Deliver AI-Powered Psoriasis Management197SHANGHAI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, and Shanghai Fosun Pharmaceutical (Group)...
► Artikel lesen
28.10.Fosun Pharma Announces 2025Q3 Financial Results473Innovative Achievements Continue to Come to Fruition, Revenue from Innovative Drugs Exceeding RMB6,700 Million in The First Three Quarters of 2025 SHANGHAI, Oct....
► Artikel lesen
28.10.FOSUN PHARMA (02196): VOLUNTARY ANNOUNCEMENT - THE PROPOSED PLANNING OF THE SPIN-OFF LISTING OF FOSUN ADGENVAX ON THE STOCK EXCHANGE2
28.10.FOSUN PHARMA (02196): REVISION OF ANNUAL CAP OF CONTINUING CONNECTED TRANSACTION1
28.10.FOSUN PHARMA (02196): 2025 THIRD QUARTERLY REPORT4
24.10.FOSUN PHARMA (02196): OVERSEAS REGULATORY ANNOUNCEMENT - ANNOUNCEMENT IN RELATION TO THE APPROVAL FOR DRUG REGISTRATION OF A SUBSIDIARY3
23.10.FOSUN PHARMA (02196): POLL RESULTS OF THE RESOLUTIONS PROPOSED AT THE 2025 FIRST EXTRAORDINARY GENERAL MEETING HELD ON THURSDAY, 23 OCTOBER 20252
Weiter >>
74 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1